With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110-70-3,N1,N2-Dimethylethane-1,2-diamine,as a common compound, the synthetic route is as follows.
To a solution of N,N’-dimethylethylenediamine (300 mg) in DMF (2.0 mL) was added K2CO3 (1.0 g) and compound B (466 mg). The mixture was heated at 80C for 3h. Solvent was evaporated and the residue was extracted with DCM and then purified by a prep-TLC plate (10%MeOH/DCM with 1% NH3 in methanol) to give product as a yellow solid (400 mg, yield 75%).
As the paragraph descriping shows that 110-70-3 is playing an increasingly important role.
Reference£º
Patent; ARIAD PHARMACEUTICALS, INC.; ZHU, Xiaotian; WANG, Yihan; SHAKESPEARE, William, C.; HUANG, Wei-Sheng; DALGARNO, David, C.; WO2013/169401; (2013); A1;,
Chiral nitrogen ligands in late transition metal-catalysed asymmetric synthesis¡ªI. Addressing the problem of ligand lability in rhodium-catalysed hydrosilations
Nitrogen-Containing Ligands for Asymmetric Homogeneous and Heterogeneous Catalysis